Exelixis' (EXEL) CEO Mike Morrissey on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/07/20
Exelixis Announces Second Quarter 2020 Financial Results and Provides Corporate UpdateBusiness Wire • 08/06/20
Exelixis to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020Business Wire • 07/29/20
Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell CarcinomaBusiness Wire • 07/20/20
Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate CancerBusiness Wire • 06/30/20
Exelixis, Inc. (EXEL) CEO Mike Morrissey at BofA Securities Napa Biopharma Conference Call - (Transcript)Seeking Alpha • 06/25/20
Exelixis, Inc. (EXEL) Presents at BMO Capital Markets Prescription for Success Healthcare Broker Conference Call - (Transcript)Seeking Alpha • 06/24/20
Exelixis Inc (EXEL) CEO Michael Morrissey Presents at Goldman Sachs Global Healthcare Conference (Transcript)Seeking Alpha • 06/11/20
Exelixis (EXEL) Down 11.5% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/04/20
Exelixis, Inc.'s (EXEL) CEO Michael Morrissey on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/06/20